NRXP

In March 2026, the company reported its full-year 2025 results, highlighting reduced operating expenses, $7.8 million cash on hand, and anticipated FDA approval of its preservative-free ketamine therapy (NRX-100) as early as Q3 2026, leading to a stock increase of 20.34%. In April 2026, NRx Pharmaceuticals welcomed a Presidential Initiative aimed at accelerating the approval of psychedelic medications, resulting in a gain of 25.49% on the day. Also in April 2026, the company announced positive FDA Office of Generic Drugs feedback on its preservative-free ketamine program and the appointment of Glenn Tyson as its first Chief Commercial Officer. In May 2026, NRx Pharmaceuticals announced the initiation of commercial manufacturing for its preservative-free ketamine product (NRX-100) and the FDA cleared NRX Pharmaceuticals to proceed with a clinical trial of NRX-101 in combination with robotic-enabled Transcranial Magnetic Stimulation. In April 2026, short interest in NRXP rose by 29.4% to 3,248,961 shares, representing about 10.5% of the float.